Cheng Xie

5PUBLICATIONS
0CO-AUTHORS
HaematologyRespiratory diseasesCardiology (incl. cardiovascular diseases)Genomics and transcriptomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 28, 2022
Are there other factors that influence the assessment of bleeding risk comparing potent P2Y12 inhibitors with clopidogrel?

Cheng Xie, Yuzhen Zhang, Jia Lin

|Sep 04, 2022
What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better? Letter regarding the article 'Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry'.

Cheng Xie, Yuzhen Zhang, Jia Lin

|Apr 27, 2022
Could angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor be used in heart failure patients with atrial fibrillation and low blood pressure? Letter regarding the article 'Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology'.

Cheng Xie

|Nov 21, 2020
Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta-analysis.

Cheng Xie, Yongfu Hang, Jianguo Zhu

|Dec 19, 2019
Comparison of the prediction performance of different warfarin dosing algorithms based on Chinese patients.

Cheng Xie, Ling Xue, Yuzhen Zhang

Pageof 1

Frequent Collaborators